参考文献/References:
[1]王永云,靳文,俞兰.胃癌相关基因及靶向治疗的研究进展[J].医学综述,2020,26(19):3814-3819.[2]Song Z,Wu Y,Yang J,et al.Progress in the treatment of advanced gastric cancer[J].Tumour Biol,2017,39(7):1010428317714626.[3]Yung-Jue B,Eric Van C,Andrea F,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,open-label,randomised controlled trial[J].The Lancet,2010,376(9742):687-697.[4]Kohei S,Yoshitaka H,Yasushi O,et al.Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma:a subgroup analysis of the GATSBY study[J].Asia-Pacific Journal of Clinical Oncology,2020,16(1):5-13.[5]沈源,保丽玲,吴桂霞,等.淋巴管密度、微血管密度与VEGF在胃癌中的生物学意义[J].暨南大学学报:自然科学与医学版,2018,39(3):223-228.[6]Xu Z Y,Hu C,Chen S Q,et al.Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil[J].Cancer management and research,2019,11:4905-4915.[7]Yang Y,Wu X W,Li F F,et al.Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer[J].Journal of cancer research and therapeutics,2019,15(2):365-369.[8]时越.雷莫芦单抗治疗晚期胃癌的研究现状[J].现代医学,2017,45(2):314-316.[9]Huang H.Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances[J].Sensors (Basel,Switzerland),2018,18(10):3249.[10]Shah M A,Starodub A,Sharma S,et al.Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a phase I study[J].Clinical cancer research : an official journal of the American Association for Cancer Research,2018,24(16):3829-3837.[11]Sahin U,Koslowski M,Dhaene K,et al.Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development[J].Clin Cancer Res,2008,14(23):7624-34.[12]Baek J H,Park D J,Kim G Y,et al.Clinical Implications of claudin18.2 expression in patients with gastric cancer[J].Anticancer research,2019,39(12):6973-6979.[13]Jiang H,Shi Z,Wang P,et al.Claudin18.2-Specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer[J].Journal of the National Cancer Institute,2019,111(4):409-418.[14]韦炜,蒋敬庭,吴昌平.胃癌中PD-L1的表达及PD-1/PD-L1抑制剂应用研究进展[J].临床检验杂志,2017,35(5):363-365.[15]凌佳音,韩涛,潘海邦,等.纳武利尤单抗治疗晚期胃癌临床研究进展[J].中国肿瘤临床,2020,47(15):792-797.[16]Kelly R J.Immunotherapy for esophageal and gastric cancer[J].Am Soc Clin Oncol Educ Boo,2017,37:292-300.[17]Boku N,Ryu M H,Kato K,et al.Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated,unresectable,advanced,or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized,phase II trial (ATTRACTION-4)[J].Ann Oncol,2019,30(2):250-258.[18]Kanae E,Osamu H,Yusuke M,et al.Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways[J].Cancer science,2016,107(4):391-397.[19]宋一萌,李明真,马潞林.花生四烯酸代谢产物与肿瘤发生和发展的研究进展[J].临床泌尿外科杂志,2017,32(3):236-240.[21]Yuan-Chuen W,Kai-Ming H.In vitro anti-inflammatory effect of apigenin in the Helicobacter pylori-infected gastric adenocarcinoma cells[J].Yuan-Chuen Wang;Kai-Ming Huang,2013,53:376-83.[22]Min L,Aixin S,Hongxian P,et al. Safety,tolerability,and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects[J].Journal of Ethnopharmacology,2014,156:210-215.